Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01583283|
Recruitment Status : Active, not recruiting
First Posted : April 24, 2012
Last Update Posted : November 30, 2017
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: ACY-1215 Drug: lenalidomide Drug: Dexamethasone||Phase 1 Phase 2|
This is phase 1, single-arm, multicenter, open-label study in patients with relapsed or relapsed/refractory MM. The study employs a sequential group dose-escalation design to determine the DLT and MTD of ACY-1215 in combination with lenalidomide and dexamethasone, all administered orally (PO). The safety, tolerability, single- and multiple-dose PK, pharmacodynamics, and anti-tumor activity of ACY 1215 in combination with lenalidomide and dexamethasone also will be evaluated.
Each cohort will enroll 3 patients. Study drug doses will be escalated sequentially after the Safety Review Committee (SRC) reviews safety data collected in C1 (28 days) from patients enrolled at the current dose level as well as emerging data from ongoing studies of ACY-1215. If there are no DLTs (as defined in Section 5.2.6) during C1 or concerns based on data from other ongoing studies, the study will proceed with dose escalation to the next cohort following safety data review by the SRC. If 1 of 3 patients has a DLT, then up to 3 additional patients will be enrolled in that cohort; if none of the additional 3 patients experience a DLT during C1, escalation may then continue to the next cohort following SRC review. If 2 or more patients have DLTs during C1, the DLT dose level will have been reached.
The MTD is defined as the dose level immediately below the DLT dose level. A total of up to 6 additional patients may be enrolled at the MTD or other appropriate dose level to obtain additional AE, PK, pharmacodynamic, and anti-tumor activity data on ACY 1215 in combination with lenalidomide and dexamethasone.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II, Open Label, Multicenter Study of ACY-1215 in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma|
|Actual Study Start Date :||July 12, 2012|
|Estimated Primary Completion Date :||March 30, 2018|
|Estimated Study Completion Date :||March 30, 2018|
Experimental: ACY-1215, Lenalidomide and dexamethasone
Open label dosing cohorts will evaluate oral ACY-1215 (doses ranging from 40 - 480 mg days 1-5, 8-12, 15-19) in combination with oral Lenalidomide (doses ranging from 15 - 25 mg days 1-21) and oral dexamethasone (40 mg once weekly).
Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.
Other Name: Histone deacetylase inhibitorDrug: lenalidomide
Dosed on Days 1-21 of a 28 day cycle.
Other Name: RevlimidDrug: Dexamethasone
Dosed on Days 1, 8, 15 and 22 of a 28 day treatment cycle.
Other Name: steroid
- Establish optimal dose of ACY-1215 in combination with lenalidomide and dexamethasone [ Time Frame: Upon completion of a 28 day treatment cycle ]
Determine maximum tolerated dose (MTD) of combination therapy. Patients will be assessed for dose-limiting toxicities (DLT) at each visit during Cycle 1.
During the second part of the study, investigate efficacy of the dose determined during the first part of the study by objective response rate and progression-free survival.
- Evaluate safety by assessing toxicities [ Time Frame: Upon completion of a 28 day treatment cycle ]Evaluate safety by assessing possible toxicities of thrombocytopenia, neutropenia, serum creatinine, total bilirubin, diarrhea, and/or vomiting.
- Determine the preliminary anti-tumor activity of ACY-1215 in combination with lenalidomide and dexamethasone [ Time Frame: Up to 24 weeks ]Change in M-protein (baseline to the end of each 28 day cycle, up to 24 weeks), objective response rate assessed according to the IMWG criteria (baseline, every other day 15 of each cycle, up to 24 weeks).
- Area under the plasma concentration versus time curve (AUC) [ Time Frame: Upon completion of a 28 day cycle. ]AUC of ACY-1215 and lenalidomide
- Changes in acetylated tubulin and acetylated histone levels [ Time Frame: Up to 24 weeks ]Evaluation of changes in acetylated tubulin(blood and bone marrow)and acetylated histones (blood and bone marrow)at baseline and post-treatment (Day 1 and up to week 24)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01583283
|United States, Massachusetts|
|Dana Farber Cancer Institute|
|Boston, Massachusetts, United States, 02215|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 2114|
|United States, North Carolina|
|University of North Carolina|
|Chapel Hill, North Carolina, United States, 27599|
|United States, Tennessee|
|Sarah Cannon Research Institute Drug Development Unit|
|Nashville, Tennessee, United States, 37203|
|United States, Washington|
|Fred Hutchinson Cancer Research Center|
|Seattle, Washington, United States, 98109|
|Principal Investigator:||Noopur Raje, MD||Massachusetts General Hospital|